Target intelligence / Profile preview

Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3) (DSG1/3)

Target
DSG1/3
Molecular classification
Cadherin superfamily, Desmosomal cadherin, Cell adhesion molecule
01

Overview

Keratinocyte intercellular adhesion proteins, primarily represented by the desmoglein family (DSG1 and DSG3), are essential transmembrane glycoproteins that form the core of desmosomes, the specialized junctions responsible for strong cell-cell adhesion in the epidermis. These proteins belong to the cadherin superfamily and mediate calcium-dependent adhesion between adjacent keratinocytes, ensuring the structural integrity of the skin and mucous membranes. In autoimmune diseases such as pemphigus vulgaris and pemphigus foliaceus, autoantibodies target these proteins, leading to the loss of adhesion (acantholysis) and the formation of life-threatening blisters. Therapeutic strategies focus on reducing the levels of these pathogenic autoantibodies through B-cell depletion (e.g., rituximab) or FcRn inhibition (e.g., efgartigimod), as well as experimental approaches like chimeric autoantibody receptor (CAAR) T-cell therapy designed to specifically eliminate autoreactive B cells.

Other names
Keratinocyte intercellular adhesion proteinsDesmosomal cadherinsPemphigus antigensDSG1DSG3Desmocollin
02

Mechanism of action

B-cell depletion, inhibition of neonatal Fc receptor (FcRn) to increase IgG clearance, systemic immunosuppression, and targeted chimeric autoantibody receptor T-cell therapy.

03

Biological functions

Cell-cell adhesionEpidermal barrier formationTissue integritySignal transduction
04

Disease associations

Pemphigus vulgarisPemphigus foliaceusParaneoplastic pemphigusStaphylococcal scalded skin syndrome
05

Safety considerations

Increased risk of secondary infections due to immunosuppressionInfusion-related reactionsSkin fragility and mucosal erosionsLong-term corticosteroid side effects
06

Interacting drugs

Rituximab

4 more in the full profile.

07

Biomarkers

Anti-Desmoglein 1 (DSG1) autoantibody titerAnti-Desmoglein 3 (DSG3) autoantibody titerDirect immunofluorescence (DIF) of skin biopsy

Beyond the preview

Go deeper on Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3) (DSG1/3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3) (DSG1/3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call